Clinical Study | Open Access
Shigeru Honda, Takayuki Nagai, Naoshi Kondo, Masahide Fukuda, Sentaro Kusuhara, Yasutomo Tsukahara, Akira Negi, "Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye", Journal of Ophthalmology, vol. 2010, Article ID 206837, 7 pages, 2010. https://doi.org/10.1155/2010/206837
Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
Purpose. Choroidal neovascularization (CNV) is often associated with age-related macular degeneration (AMD) and pathological myopia (PM). Bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic effects. The purpose of this study is to investigate the therapeutic effects of oral bisphosphonates for CNV in humans. Methods. Thirty-six consecutive cases with CNV due to AMD or PM who declined anti-VEGF therapy were recruited. The patients were prescribed 5 mg of oral alendronates daily for 6 months. The best-corrected visual-acuity (BCVA), the lesion size in fundus photographs and fluorescein angiography, foveal thickness and total macular volume in optical coherence tomography were compared between pre- and post-treatment. Results. The mean BCVA of the patients was significantly improved after a months with the treatment in the AMD group. In the PM group, the mean BCVA was maintained up to 6 months with the treatment. The mean lesion size was significantly decreased by 3 months in both groups. The averages of foveal thickness and total macular volume were significantly reduced after 1 month of treatment in the AMD group.Conclusions. Oral bisphosphonate should be further investigated as a possible therapeutic and preventive drug for CNV due to AMD and PM.
Choroidal neovascularization (CNV) is a major cause of adult blindness and is often associated with age-related macular degeneration (AMD) and pathological myopia or other macular diseases. Current therapies for CNV are represented by repeated intravitreal injections of antivascular endothelial growth factor (VEGF) antibodies or aptamer [1, 2]. They require periodic reinjections of the antibody or aptamer every 4–6 weeks for many years to keep the lesion stable and to maintain vision, or else visual acuity was reported to be reduced . These retreatments may pose a cumulative risk for ocular and systemic complications such as endophthalmitis and strokes [4–6] and pose a burden on both the patients and health care systems. Hence, we are interested in alternative therapies using oral drugs or eye drops, since they are usually less expensive, easier to use to treat a broad range of patients, and may also be used for prevention .
Bisphosphonates are powerful inhibitors of osteoclasts, and are commonly used as the drug of choice to treat and prevent osteoporosis . Recent studies have demonstrated that the antitumor and antiangiogenic effects induced by suppressing VEGF expression are associated with bisphosphonates, which opens up novel possibilities for this drug class and raises new areas of research for tumorigenesis and angiogenesis [9–12]. However, in ophthalmology, bisphosphonates are known only as drugs that may cause uveitis, scleritis, or orbital inflammation as rare side effects [13–15]. Although bisphosphonates were thought to accumulate mostly in the bone tissue, we suspected that bisphosphonates may have good permeability into the eye, even to the point of causing side effects in rare cases. Following these insights, we recently demonstrated the inhibitory effects of bisphosphonates on laser-induced choroidal neovascularization (CNV) due to suppressed VEGF expression in mice, and hypothesized about the therapeutic effects of this drug in human CNV associated with AMD and related diseases .
Therefore, we conducted a preliminary prospective study, in which we administered oral bisphosphonates to 36 cases of CNV secondary to AMD and pathological myopia, and found that oral bisphosphonates significantly inhibited CNV in these patients.
The cohort included 40 eyes from 36 consecutive patients with CNV secondary to AMD and pathological myopia (25 eyes of 24 AMD cases and 15 eyes of 12 pathological myopia cases), who declined intravitreal injections of anti-VEGF drugs or had systemic risks for strokes. Since both types of CNV are known to respond to anti-VEGF therapy [1, 17], we included both phenotypes in the present study. The CNV was determined by slit-lamp biomicroscopes of the fundi, 50 degree color fundus photographs, optical coherence tomographies (OCT) (Stratus or Cirrus OCT, Carl Zeiss Meditec Japan, Tokyo, Japan), fluorescein angiographies (FA) and indocyanine green angiography (ICG). All CNV cases included subfoveal lesions accompanied by serous retinal detachments and subretinal hemorrhages in this study. The AMD cases (25 eyes) included all 3 lesion types, namely, predominantly classic (6 eyes), minimally classic (11 eyes) and occult with no classic (8 eyes), lesions determined by FA. Eleven cases with recurrent CNV once maintained by photodynamic therapy (PDT) from 3 months to two years ago were also included in the AMD cases. Cases of polypoidal choroidal vasculopathy (PCV) were diagnosed by ICG and were excluded from this study since PCV is not thought as typical CNV . Pathological myopia was diagnosed by an axial length over 26.5 mm and the corresponding fundus findings. No patients received prior treatment in the myopia cases. The summarized clinical data of the enrolled patients are shown in Table 1. The visual acuities were determined using a Landolt C chart and were converted to a logarithm of the minimum angle of resolution (LogMAR) for calculation and description. The lesion size was analyzed by NIH image J software using digital images. Specifically, the lesion size was determined as the combined area of dye leakage at 5 minutes in FA and hemorrhage in fundus photography and was quantified by the number of pixels. All subjects were masked for patient ID, clinical course, and the date of examinations.
|BCVA: best corrected visual acuity, LogMAR: logarithm of the minimum angle of resolution.|
Under approval by the Kobe University institutional review board and informed consent from all the patients, 5 mg of oral alendronates (Teijin Pharma. Ltd., Tokyo, Japan) were prescribed daily for six months. The patients were informed about the side effects of bisphosphonates (e.g., gastritis, arthralgia, uveitis) and were advised to consult their physician if they felt any unusual symptoms. Medication compliance was checked by interview and ophthalmological examinations, including the best-corrected visual-acuity (BCVA), color fundus photographs, and OCT, which were performed monthly. Fluorescein angiographies were repeated at three months posttreatment.
The LogMAR BCVA was evaluated as the main outcome of the treatment. The change in lesion size found from fundus photographs and FA, the foveal thickness (average of central 1 mm circle), and the total macular volume determined automatically by a 6 mm retinal map from Stratus OCT and by a retinal map from Cirrus OCT were also assessed over the treatment period. The OCT system used in each patient was consistent throughout the follow-up period.
For statistical analysis, Wilcoxon signed-rank test was used for the BCVA, lesion size, foveal thickness, and total macular volume. values less than.05 were considered to be statistically significant
Twenty-one eyes of 20 AMD cases were ultimately followed-up for 6 months, since three cases self-discontinued and one preferred photodynamic therapy after 3 months of medication. Fourteen eyes of 11 pathological myopia cases were followed-up for 6 months, but one case discontinued medication after 3 months because of bilateral uveitis, which resolved with topical steroids.
The mean BCVA of the patients was significantly improved after a month with the treatment in the AMD group (Figure 1). Comparing the proportions of BCVA between pretreatment and after 6 months of the treatment, the number of eyes in which BCVA improved more than 0.2 LogMAR,, changed within 0.2 LogMAR and deteriorated more than 0.2 LogMAR were 5 (24%), 15 (71%), and 1 (5%) eyes, respectively in the AMD group, whereas those in the pathological myopia group were 2 (14%), 9 (64%), and 3 (22%) eyes, respectively. The mean lesion sizes determined in FA and fundus photograph were significantly decreased after 3 months of the treatment in both groups (Figure 2). The mean foveal thickness (Figure 3) and total macular volume (Figure 4) measured by OCT were significantly decreased in the AMD group after a month with the treatment. No adverse systemic side effects were found or self-reported in any of the present cases. The detailed findings from selected cases of the responders are shown in Figures 5, 6, and 7.
In our preliminary study, we found that oral bisphosphonates stopped the progression of CNV due to AMD and pathological myopia in 40 eyes from 36 patients. Their BCVA was maintained for at least 6 months, and the measured lesion size was significantly reduced with the treatment. In the AMD group, OCT revealed a significant improvement in foveal thickness and total macular volume at one month after the treatment, and further improvements were observed up to 6 months with the treatment.
Although recent studies have demonstrated that antitumor and antiangiogenic effects are associated with bisphosphonates [9–12], in the field of ophthalmology, they are regarded only as drugs that may cause ocular inflammation in certain individuals [13–15]. Therefore, this is the first study which reports beneficial ocular effects of bisphosphonates. CNV due to AMD and pathological myopia is a representative idiopathic angiogenic disorder and a major age-related disorder in addition to osteoporosis, and the number of patients suffering from these pathologies has increased remarkably over recent years [18, 19]. Hence, many elderly people face the risk of both diseases. Therefore, we considered that oral bisphosphonates might be beneficial for both osteoporosis and AMD. The current therapies for CNV accompanied by AMD and pathological myopia consist of repeated intravitreal injections of anti-VEGF antibodies [1, 17]. Anti-VEGF therapy requires monthly re-injections of the antibodies for a long period to maintain vision, which poses a cumulative risk for ocular and systemic complications [4–6]. Moreover, they are not suitable for the prevention of disease. Hence, recent reviews have pointed out the need for an optimal strategy for anti-VEGF therapy, including combinations with other therapies [1, 20, 21].
Autoradiography with an intraperitoneal administration of [14C]-alendronate in mice revealed that it accumulates not only into the bone tissue, but also in the eye , particularly in the choroidal tissues (personal communication with Teijin Pharma. Ltd.). This may explain the delivery of oral alendronates to CNV lesions. Alendronate is a nitrogen-containing bisphosphonate (N-BP) which inhibits famesyl diphosphonate synthase in the biosynthetic mevalonate pathway. Likewise, statins are known to suppress CNV via an inhibition of mevalonate synthesis . Recent reports have demonstrated that N-BP inhibits the expression of VEGF, matrix metalloproteinase (MMP), and the integrin families to inhibit angiogenesis both in vitro and in vivo [8–11, 16]. The involvement of MMP and integrins as well as VEGF in CNV formation has been well documented . Alendronate may suppress CNV via a direct inhibition of the proliferation of vascular endothelial cells , and by regulating cellular angiogenic gene expression [16, 26, 27]. In addition, bisphosphonates are known to control the inflammation induced by macrophages and mononuclear cells [28–30]. Although AMD is strongly associated with several molecules which have important roles in inflammation [31, 32], a recent report suggested that myopic CNV is not associated with these molecules . This may explain the better response of AMD to bisphosphonates than myopic CNV.
Currently, a number of bisphosphonates have been developed, and some of them are exempt from serious ocular adverse events . The broad beneficial effects of bisphosphonates are being investigated in many research areas besides osteoporosis, especially tumorigenesis. Hence, we considered that the effects of oral bisphosphonates may be further investigated as a therapeutic drug for CNV, including AMD and pathological myopia. Moreover, the combination of oral bisphosphonates with anti-VEGF therapy can be further investigated since it may reduce the number of anti-VEGF therapy visits required.
Due to the small sample size and non-randomized controlled study, a definitive conclusion may not be drawn from these results, and further studies including a randomized controlled trial and comparisons with other therapies such as intravitreal ranibizumab are required to confirm the safety and efficacy of bisphosphonates in the eye. However, it is interesting that our previous study using photodynamic therapy to treat AMD did not improve the mean visual acuity of the patients, which might imply some advantages of oral bisphosphonates for specific AMD patients. Our goal is to determine whether bisphosphonates are useful as preventative or supportive drugs for current anti-VEGF therapy in CNV treatment. The present study gave a novel and totally different insight into the use of this drug class in ophthalmology and suggested a new possibility for the management of CNV accompanied by AMD or pathological myopia.
We treated patients with choroidal neovascularization (CNV) due to age-related macular degeneration and pathological myopia with oral bisphosphonates and found their remarkable therapeutic effect on CNV for the first time. Our findings suggest a beneficial effect of bisphosphonates in the treatment, and perhaps the prevention, of CNV for the future.
- L. J. Hernandez-Pastor, A. Ortega, A. Garcia-Layana, and J. Giraldez, “Ranibizumab for neovascular age-related macular degeneration,” American Journal of Health-System Pharmacy, vol. 65, no. 19, pp. 1805–1814, 2008.
- B. Morris, F. Imrie, A.-M. Armbrecht, and B. Dhillon, “Age-related macular degeneration and recent developments: new hope for old eyes?” Postgraduate Medical Journal, vol. 83, no. 979, pp. 301–307, 2007.
- P. A. Keane, K. T. Chang, S. Liakopoulos, R. V. Jivrajka, A. C. Walsh, and S. R. Sadda, “Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular AMD,” Retina, vol. 29, no. 5, pp. 592–600, 2009.
- D. R. Fintak, G. K. Shah, and G. K. Shah, “Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab,” Retina, vol. 28, no. 10, pp. 1395–1399, 2008.
- S. Pilli, A. Kotsolis, and A. Kotsolis, “Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting,” American Journal of Ophthalmology, vol. 145, no. 5, pp. 879–882, 2008.
- T. Ueta, Y. Yanagi, Y. Tamaki, and T. Yamaguchi, “Cerebrovascular accidents in ranibizumab,” Ophthalmology, vol. 116, no. 2, p. 362.e1, 2009.
- S. Moore, “Facilitating oral chemotherapy treatment and compliance through patient/family-focused education,” Cancer Nursing, vol. 30, no. 2, pp. 112–122, 2007.
- J. R. Green, “Bisphosphonates: preclinical review,” Oncologist, vol. 9, no. 4, pp. 3–13, 2004.
- M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon, “Emerging anti-cancer molecular mechanisms of aminobisphosphonates,” Endocrine-Related Cancer, vol. 13, no. 1, pp. 7–26, 2006.
- D. Santini, G. Schiavon, and G. Schiavon, “Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?” Recent patents on anti-cancer drug discovery, vol. 1, no. 3, pp. 383–396, 2006.
- D. Santini, B. Vincenzi, and B. Vincenzi, “Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients,” Clinical Cancer Research, vol. 13, no. 15, pp. 4482–4486, 2007.
- U. Bäckman, A. Svensson, R. H. Christofferson, and F. Azarbayjani, “The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis,” Anticancer Research, vol. 28, no. 3A, pp. 1551–1557, 2008.
- F. W. Fraunfelder, “Ocular side effects associated with bisphosphonates,” Drugs of Today, vol. 39, no. 11, pp. 829–835, 2003.
- F. W. Fraunfelder and F. T. Fraunfelder, “Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects,” Ophthalmology, vol. 111, no. 7, pp. 1275–1279, 2004.
- N. S. Sharma, J.-L. Ooi, K. Masselos, M. J. Hooper, and I. C. Francis, “Zoledronic acid infusion and orbital inflammatory disease,” New England Journal of Medicine, vol. 359, no. 13, pp. 1410–1411, 2008.
- T. Nagai, H. Imai, S. Honda, and A. Negi, “Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice,” Investigative Ophthalmology and Visual Science, vol. 48, no. 12, pp. 5716–5721, 2007.
- L. Arias, N. Planas, S. Prades, J. M. Caminal, M. Rubio, O. Pujol, and G. Roca, “Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results,” British Journal of Ophthalmology, vol. 92, no. 8, pp. 1035–1039, 2008.
- D. B. Rein, J. S. Wittenborn, X. Zhang, A. A. Honeycutt, S. B. Lesesne, and J. Saaddine, “Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments,” Archives of Ophthalmology, vol. 127, no. 4, pp. 533–540, 2009.
- R. Keen, “Osteoporosis: strategies for prevention and management,” Best Practice and Research: Clinical Rheumatology, vol. 21, no. 1, pp. 109–122, 2007.
- J. L. Colquitt, J. Jones, S. C. Tan, A. Takeda, A. J. Clegg, and A. Price, “Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation,” Health Technology Assessment, vol. 12, no. 16, 2008.
- H. Dadgostar and N. Waheed, “The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration,” Eye, vol. 22, no. 6, pp. 761–767, 2008.
- T. Mochizuki, S. Nishimura, K. Okabe et al., “Metabolic fate of 4-amino-1-hydroxybutylidene-1, 1-bisphosphonate (alendronate) (II): plasma concentration, distribution and excretion after repeated intravenous administration to 7-week old rats and after single intravenous administration to 30-week old rats, and transfer into the fetus and milk in rats,” Drug Metabolism and Phamacokinetics, vol. 10, pp. 174–189, 1995 (Japanese).
- X. Bi, M. Baudry, J. Liu, Y. Yao, L. Fu, F. Brucher, and G. Lynch, “Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 48238–48245, 2004.
- A. Das and P. G. McGuire, “Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition,” Progress in Retinal and Eye Research, vol. 22, no. 6, pp. 721–748, 2003.
- K. Hashimoto, K.-I. Morishige, and K.-I. Morishige, “Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells,” Biochemical and Biophysical Research Communications, vol. 354, no. 2, pp. 478–484, 2007.
- K. Amagase, S. Hayashi, K. Nishikawa, E. Aihara, and K. Takeuchi, “Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats,” Digestive Diseases and Sciences, vol. 52, no. 8, pp. 1879–1889, 2007.
- J. H.-J. Fong and D. E. Ingber, “Modulation of adhesion-dependent cAMP signaling by echistatin and alendronate,” Biochemical and Biophysical Research Communications, vol. 221, no. 1, pp. 19–24, 1996.
- D. G. Espinosa-Heidmann, I. J. Suner, E. P. Hernandez, D. Monroy, K. G. Csaky, and S. W. Cousins, “Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 44, no. 8, pp. 3586–3592, 2003.
- E. Sakurai, A. Anand, B. K. Ambati, N. Van Rooijen, and J. Ambati, “Macrophage depletion inhibits experimental choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 44, no. 8, pp. 3578–3585, 2003.
- P. Pietschmann, P. Stohlawetz, S. Brosch, G. Steiner, J. S. Smolen, and M. Peterlik, “The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells,” Calcified Tissue International, vol. 63, no. 4, pp. 325–330, 1998.
- L. A. Hecker, A. O. Edwards, and A. O. Edwards, “Genetic control of the alternative pathway of complement in humans and age-related macular degeneration,” Human Molecular Genetics, vol. 19, no. 1, pp. 209–215, 2009.
- R. Reynolds, M. E. Hartnett, J. P. Atkinson, P. C. Giclas, B. Rosner, and J. M. Seddon, “Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes,” Investigative ophthalmology & visual science, vol. 50, no. 12, pp. 5818–5827, 2009.
- H. Nakanishi, N. Gotoh, and N. Gotoh, “ARMS2/HTRA1 and CFH polymorphisms are not associated with choroidal neovascularization in highly myopic eyes of the elderly Japanese population,” Eye, vol. 24, no. 6, pp. 1078–1084, 2010.
- H. Nakashizuka, M. Mitsumata, S. Okisaka, H. Shimada, A. Kawamura, R. Mori, and M. Yuzawa, “Clinicopathologic findings in polypoidal choroidal vasculopathy,” Investigative Ophthalmology and Visual Science, vol. 49, no. 11, pp. 4729–4737, 2008.
Copyright © 2010 Shigeru Honda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.